GO:1905180 positive regulation of cardiac muscle tissue regeneration: Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905180 describes any biological process that increases the rate, frequency, or extent of cardiac muscle tissue regeneration, the regrowth of functional myocardium after injury.
• Cardiac muscle tissue regeneration is driven primarily by cardiomyocyte proliferation, which is robust in neonatal mammals but largely lost in adults.
• Key positive regulators include PTMA, which enhances STAT3 acetylation to promote cardiomyocyte proliferation and cardiac repair.
• Non-coding RNAs, including microRNAs and long non-coding RNAs, act as positive regulators of cardiac regeneration by targeting cell-cycle and survival pathways.
• Extrinsic signals such as vagus nerve stimulation and endocardial lysozyme 2 modulate the regenerative response after myocardial infarction.
• CRISPR-based knockout, knock-in, and overexpression models are essential to test whether candidate genes causally promote cardiac muscle tissue regeneration.
Description
GO:1905180, positive regulation of cardiac muscle tissue regeneration, is a Gene Ontology biological process term that captures any molecular event that increases the rate, frequency, or extent of cardiac muscle tissue regeneration. Cardiac muscle tissue regeneration refers to the regrowth of functional myocardium after injury, a process that depends on the proliferation of cardiomyocytes and the coordinated activity of supporting cell types, extracellular matrix remodeling, and paracrine signals. In adult mammals, this regenerative capacity is severely limited, making the identification of positive regulators a central goal of cardiovascular research. Understanding GO:1905180 is therefore critical for researchers seeking to develop therapies that restore heart muscle after myocardial infarction or in heart failure. The term is defined by its outcome: any gene product, pathway, or intervention that enhances cardiac muscle regeneration qualifies as a positive regulator, whether it acts cell-autonomously in cardiomyocytes or through non-cell-autonomous mechanisms such as immune modulation or nerve stimulation.
positive regulation of cardiac muscle tissue regeneration At A Glance
| GO ID | GO:1905180 |
|---|---|
| GO term | positive regulation of cardiac muscle tissue regeneration |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Upregulation of processes that increase the rate, frequency, or extent of cardiac muscle tissue regeneration |
| Biological context | Cardiac injury, myocardial infarction, heart failure, neonatal heart regeneration |
| Key cell types | Cardiomyocytes, cardiac fibroblasts, endothelial cells, immune cells |
| Representative regulators | PTMA, STAT3, non-coding RNAs, lysozyme 2, vagus nerve signaling |
| Research relevance | Target discovery for regenerative cardiology and CRISPR-based functional screens |
What Is GO:1905180?
In our own words, GO:1905180 encompasses all biological processes that positively regulate cardiac muscle tissue regeneration. This includes molecular signals that promote cardiomyocyte proliferation, survival, or dedifferentiation; paracrine factors that recruit or activate regenerative cell populations; and systemic or neural inputs that create a pro-regenerative environment after injury. The term is not restricted to a single cell type or pathway; rather, it integrates any mechanism that increases the extent or efficiency of new heart muscle formation.
Why Is positive regulation of cardiac muscle tissue regeneration Important in Cell Biology?
GO:1905180 is important because it defines the molecular logic of heart regeneration, a process that is robust in neonatal mammals but largely lost in adults. Identifying positive regulators of cardiac muscle tissue regeneration can reveal therapeutic targets to restore myocardium after myocardial infarction, prevent heart failure progression, and improve outcomes in congenital heart disease. Because the term is defined by functional outcome rather than a single pathway, it provides a flexible framework for integrating diverse signals, from transcription factors and non-coding RNAs to neural and immune inputs.
• Defines the molecular basis of cardiac regeneration, a major unmet need in cardiovascular medicine.
• Provides a framework to study cardiomyocyte proliferation, the primary driver of new muscle formation.
• Links non-coding RNA networks to regenerative outcomes, offering RNA-based therapeutic opportunities.
• Highlights the role of extrinsic signals such as vagus nerve stimulation in promoting repair.
• Includes endocardial and immune-derived factors that modulate the regenerative niche.
• Supports CRISPR functional genomics to identify causal positive regulators.
• Relevant to myocardial infarction, heart failure, and pediatric cardiac disease.
• Guides development of cell models for drug screening and target validation.
• Connects cardiac regeneration to broader processes like angiogenesis and fibrosis resolution.
• Enables cross-species comparisons of regenerative capacity.
What Happens During positive regulation of cardiac muscle tissue regeneration?
Initiation of the regenerative response after injury
In simple terms: When the heart is injured, it sends out alarm signals that start the repair process.
After myocardial infarction or other injury, cardiomyocyte death triggers inflammatory and stress signals that initiate a regenerative response. Positive regulation of cardiac muscle tissue regeneration begins with the activation of pro-survival and pro-proliferative pathways in surviving cardiomyocytes and supporting cells. Endocardial cells can release factors such as lysozyme 2 that modulate remote injury signals and promote rapid recovery. The initial phase also involves immune cell recruitment and clearance of dead cells, which sets the stage for subsequent regeneration.
Cardiomyocyte proliferation and cell-cycle re-entry
In simple terms: Heart muscle cells divide to make new muscle, but adult cells usually stop dividing.
The central mechanism of cardiac muscle tissue regeneration is cardiomyocyte proliferation, which requires re-entry into the cell cycle. PTMA (prothymosin alpha) promotes cardiomyocyte proliferation by enhancing STAT3 acetylation, leading to increased cardiac repair in experimental models. Neonatal mammals retain a robust proliferative capacity, but this is largely lost in adults due to cell-cycle exit and polyploidization. Positive regulators of GO:1905180 therefore often target cell-cycle checkpoints, transcription factors, or epigenetic barriers to proliferation.
Non-coding RNA regulation of regeneration
In simple terms: Small RNA molecules can turn genes on or off to help the heart repair itself.
Non-coding RNAs, including microRNAs and long non-coding RNAs, act as positive regulators of cardiac regeneration by modulating gene expression programs. Specific microRNAs can promote cardiomyocyte proliferation by repressing cell-cycle inhibitors, while others enhance survival or angiogenesis. Long non-coding RNAs can scaffold chromatin-modifying complexes to activate regenerative gene networks. These RNA-based mechanisms are attractive therapeutic targets because they can be manipulated with mimics or inhibitors.
Extrinsic and neural modulation of regeneration
In simple terms: Nerves and other body signals can help the heart heal faster.
The regenerative response is not cell-autonomous; it is influenced by neural and systemic signals. Optogenetic stimulation of the cardiac vagus nerve promotes heart regenerative repair after myocardial infarction, demonstrating that neural inputs can positively regulate GO:1905180. Endocardial cells and remote injury signals also contribute to the regenerative niche. These extrinsic mechanisms offer non-pharmacological or targeted approaches to enhance cardiac repair.
Extracellular matrix remodeling and resolution of fibrosis
In simple terms: The scar tissue must be remodeled to allow new muscle to form.
For cardiac muscle tissue regeneration to proceed, the extracellular matrix must be remodeled and excessive fibrosis limited. Thrombospondin 1 and Reelin act through Vldlr to regulate cardiac growth and repair, influencing the balance between fibrosis and regeneration. Positive regulation of GO:1905180 therefore includes signals that promote a permissive matrix environment and resolve scar tissue. This stage is critical because persistent fibrosis impedes new muscle formation.
Key Genes Involved in GO:1905180 positive regulation of cardiac muscle tissue regeneration
The following genes and proteins have been experimentally linked to positive regulation of cardiac muscle tissue regeneration or closely related regenerative processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTMA | Enhances STAT3 acetylation to promote cardiomyocyte proliferation and cardiac repair | Direct positive regulator of cardiac regeneration; validated in mouse models |
| STAT3 | Transcription factor downstream of PTMA; promotes cardiomyocyte proliferation and survival | Key effector of pro-regenerative signaling |
| Vldlr | Receptor for Reelin and thrombospondin 1; regulates cardiac growth and repair | Modulates regenerative signaling in the heart |
| Thrombospondin 1 | Extracellular matrix protein that acts through Vldlr to regulate cardiac repair | Influences fibrosis and regenerative outcomes |
| Reelin | Extracellular matrix protein that signals through Vldlr in cardiac growth and repair | Potential regulator of cardiac regeneration |
| Lysozyme 2 | Endocardial factor that modulates remote injury signals and promotes recovery | Target for enhancing cardiac repair |
| HSF1 | Stress-responsive transcription factor; in skeletal muscle regulates SIRT3-PGC1α axis | May inform stress-related regenerative mechanisms |
| SIRT3 | Mitochondrial deacetylase; downstream of HSF1 in muscle | Linked to mitochondrial function in muscle aging |
| PGC1α | Master regulator of mitochondrial biogenesis | Downstream of HSF1-SIRT3 axis in muscle |
| miRNAs (e.g., miR-199a, miR-590) | Non-coding RNAs that promote cardiomyocyte proliferation | Therapeutic candidates for cardiac regeneration |
| lncRNAs (e.g., NR_045363) | Long non-coding RNAs that regulate regenerative gene networks | Emerging targets in cardiac regeneration |
| Satellite cells (muscle stem cells) | Stem cell population in skeletal muscle; dysfunction linked to neuromuscular disorders | Provides comparative insights into muscle regeneration |
| Vagus nerve signaling components | Neural inputs that promote regenerative repair after myocardial infarction | Non-pharmacological modulation of regeneration |
| Cardiac fibroblasts | Matrix-producing cells that influence fibrosis and regeneration | Targets for modulating the regenerative niche |
| Endothelial cells | Angiogenesis and paracrine support for regenerating myocardium | Essential for revascularization during repair |
| Immune cells (macrophages) | Clear debris and secrete pro-regenerative factors | Modulate the inflammatory phase of repair |
How Is positive regulation of cardiac muscle tissue regeneration Regulated?
Positive regulation of cardiac muscle tissue regeneration is controlled by a multilayered network of transcription factors, non-coding RNAs, and signaling pathways. PTMA enhances STAT3 acetylation to drive cardiomyocyte proliferation, illustrating how post-translational modifications regulate regenerative capacity. Non-coding RNAs fine-tune gene expression programs by targeting cell-cycle regulators and survival factors. Extrinsic signals such as vagus nerve stimulation and endocardial lysozyme 2 modulate the regenerative environment. Additionally, extracellular matrix proteins like thrombospondin 1 and Reelin act through Vldlr to balance growth and fibrosis. These regulatory layers provide multiple entry points for therapeutic intervention.
positive regulation of cardiac muscle tissue regeneration and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTMA | Myocardial infarction; cardiac repair | Cardiomyocyte-specific overexpression and knockout mice |
| STAT3 | Cardiac hypertrophy and regeneration | Conditional knockout and knock-in models |
| Vldlr | Cardiac growth and repair; fibrosis | Vldlr knockout mice |
| Lysozyme 2 | Endocardial injury response | Endocardial-specific knockout or overexpression |
| HSF1 | Age-related muscle decline | Muscle-specific knockout and transgenic models |
Myocardial infarction and heart failure
After myocardial infarction, the adult heart cannot adequately regenerate muscle, leading to scar formation and heart failure. Positive regulators of GO:1905180, such as PTMA-STAT3 signaling or vagus nerve stimulation, have been shown to improve cardiac repair in preclinical models. Enhancing endogenous regenerative pathways could reduce infarct size and preserve cardiac function.
Cardiac hypertrophy and pathological remodeling
Pathological cardiac hypertrophy involves maladaptive growth that often progresses to heart failure. In contrast, physiological hypertrophy is associated with beneficial adaptation. Understanding how positive regulation of cardiac muscle tissue regeneration intersects with hypertrophic signaling may reveal strategies to promote adaptive rather than maladaptive remodeling.
Neuromuscular disorders and muscle regeneration
Muscle satellite cell dysfunction contributes to neuromuscular disorders, highlighting the importance of stem cell-mediated regeneration in muscle tissues. Although this primarily concerns skeletal muscle, comparative insights may inform cardiac regeneration research. Shared mechanisms of stem cell activation and differentiation could be relevant to GO:1905180.
Age-related muscle decline
Aging is associated with reduced regenerative capacity in muscle tissues. In skeletal muscle, HSF1 alleviates age-associated sarcopenia and mitochondrial decline via the SIRT3-PGC1α axis. Similar aging-related mechanisms may limit cardiac regeneration, suggesting that targeting stress-response pathways could enhance cardiac repair in older individuals.
From positive regulation of cardiac muscle tissue regeneration-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PTMA promote cardiomyocyte proliferation? | Cardiomyocyte-specific PTMA overexpression and knockout mice |
| Is STAT3 acetylation required for cardiac repair? | STAT3 acetylation-site point-mutant knock-in mice |
| Does Vldlr mediate Reelin/thrombospondin 1 effects? | Vldlr knockout and tagged knock-in reporter mice |
| Can non-coding RNAs enhance regeneration? | miRNA mimic/inhibitor delivery in mouse myocardial infarction models |
| Does vagus nerve stimulation promote repair? | Optogenetic stimulation in rodent myocardial infarction models |
| Does endocardial lysozyme 2 modulate recovery? | Endocardial-specific knockout and overexpression models |
How to Study the positive regulation of cardiac muscle tissue regeneration Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EdU/BrdU incorporation | DNA synthesis and cell proliferation | Quantify cardiomyocyte proliferation in vitro and in vivo |
| Lineage tracing | Origin of new cardiomyocytes | Determine whether regeneration is from pre-existing cardiomyocytes |
| RNA-seq | Global gene expression changes | Identify regenerative gene networks |
| Small RNA-seq | microRNA and other non-coding RNA expression | Discover regulatory non-coding RNAs |
| Immunoprecipitation + western blot | Protein acetylation and interactions | Assess STAT3 acetylation status |
| Echocardiography | Cardiac function (ejection fraction, fractional shortening) | Evaluate recovery after myocardial infarction |
| Histology (Masson's trichrome) | Fibrosis and infarct size | Assess scar formation and regeneration |
| Optogenetics | Neural control of cardiac repair | Stimulate vagus nerve to promote regeneration |
Lineage tracing and proliferation assays
Lineage tracing using genetic labels (e.g., Cre-lox systems) allows researchers to determine whether new cardiomyocytes arise from pre-existing cardiomyocytes. Proliferation assays such as EdU or BrdU incorporation, Ki67 staining, and phospho-histone H3 imaging quantify cell-cycle re-entry. These methods are essential to confirm that a candidate gene positively regulates cardiac muscle tissue regeneration.
Transcriptomics and non-coding RNA profiling
RNA sequencing and small RNA sequencing can identify differentially expressed mRNAs, microRNAs, and long non-coding RNAs during cardiac regeneration. These approaches reveal regulatory networks and candidate positive regulators. Integrating transcriptomic data with functional screens helps prioritize targets for CRISPR validation.
Proteomics and post-translational modification analysis
Mass spectrometry-based proteomics can detect changes in protein abundance and post-translational modifications such as acetylation. For example, STAT3 acetylation status can be assessed by immunoprecipitation followed by western blot or mass spectrometry. These methods provide mechanistic insight into how positive regulators function.
In vivo functional models
Mouse models of myocardial infarction, including permanent ligation or ischemia-reperfusion, are standard for testing regenerative interventions. Echocardiography and histological analysis of infarct size and fibrosis assess functional outcomes. Optogenetic or pharmacological modulation can be applied to test extrinsic regulators.
How CRISPR Can Be Used to Study GO:1905180 positive regulation of cardiac muscle tissue regeneration
Knockout
CRISPR knockout of candidate positive regulators (e.g., PTMA, STAT3, Vldlr) in cardiomyocytes or mouse models can test whether the gene is required for cardiac muscle tissue regeneration. Loss-of-function studies help establish causality and identify essential pathways. Conditional knockout avoids developmental lethality and allows injury-specific interrogation.
Point Mutation
Point mutations can be introduced to disrupt specific post-translational modification sites, such as STAT3 acetylation sites, to test their functional relevance in cardiac repair. CRISPR base editing or homology-directed repair can generate precise point mutants. These models are valuable for dissecting molecular mechanisms downstream of positive regulators.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) or epitope tags allows visualization and tracking of candidate proteins during regeneration. Tagged knock-in models can also facilitate chromatin immunoprecipitation or proteomic studies. Knock-in of human disease variants may reveal allele-specific effects on regenerative capacity.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression can test whether increasing a candidate gene enhances cardiac muscle tissue regeneration. Overexpression of PTMA or non-coding RNAs has been shown to promote cardiomyocyte proliferation and repair. These gain-of-function models complement knockout studies to establish sufficiency.
How EDITGENE Supports positive regulation of cardiac muscle tissue regeneration Research
Researchers studying positive regulation of cardiac muscle tissue regeneration-related genes often need to determine whether a candidate gene is causally involved in promoting cardiomyocyte proliferation, survival, or repair. Establishing causality requires precise genetic manipulation, which is where EDITGENE's CRISPR services can accelerate discovery.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of cardiac muscle tissue regeneration research.
Frequently Asked Questions About positive regulation of cardiac muscle tissue regeneration
What is GO:1905180?
GO:1905180 is a Gene Ontology biological process term for positive regulation of cardiac muscle tissue regeneration, encompassing any process that increases the rate, frequency, or extent of heart muscle regrowth after injury.
What genes are involved in positive regulation of cardiac muscle tissue regeneration?
Key genes include PTMA, STAT3, Vldlr, thrombospondin 1, Reelin, and lysozyme 2, as well as non-coding RNAs such as microRNAs and long non-coding RNAs.
How is cardiac muscle tissue regeneration regulated?
It is regulated by a multilayered network of transcription factors, non-coding RNAs, post-translational modifications, and extrinsic signals like vagus nerve stimulation.
Why is cardiac muscle tissue regeneration important?
It is critical for recovery after myocardial infarction and for preventing heart failure, as adult mammals have limited regenerative capacity.
What is the role of PTMA in cardiac regeneration?
PTMA promotes cardiomyocyte proliferation and cardiac repair by enhancing STAT3 acetylation.
Can non-coding RNAs promote cardiac regeneration?
Yes, specific microRNAs and long non-coding RNAs can positively regulate cardiac regeneration by modulating gene expression programs.
What experimental models are used to study GO:1905180?
Common models include mouse myocardial infarction, lineage tracing, CRISPR knockout/knock-in, and optogenetic vagus nerve stimulation.
How does vagus nerve stimulation affect heart repair?
Optogenetic stimulation of the cardiac vagus nerve promotes regenerative repair after myocardial infarction in preclinical models.
What is the link between endocardial lysozyme 2 and cardiac recovery?
Lysozyme 2 in the endocardium modulates remote injury signals and promotes rapid recovery after cardiac injury.
How can CRISPR help study positive regulation of cardiac muscle tissue regeneration?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of candidate genes in cardiac regeneration.
Conclusion
GO:1905180, positive regulation of cardiac muscle tissue regeneration, provides a unifying framework for understanding how diverse molecular and cellular signals enhance heart muscle repair. Key regulators such as PTMA-STAT3 signaling, non-coding RNAs, and extrinsic neural inputs offer promising therapeutic targets. Continued research using CRISPR-based models and multi-omics approaches will be essential to translate these insights into regenerative therapies for heart disease.
References
- 1. Nakamura M et al.. 2018. Mechanisms of physiological and pathological cardiac hypertrophy.. Nat Rev Cardiol 15(7):387-407 PMID: 29674714
- 2. Liu N et al.. 2025. PTMA controls cardiomyocyte proliferation and cardiac repair by enhancing STAT3 acetylation.. Sci Adv 11(21):eadt9446 PMID: 40408476
- 3. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 4. Fan C et al.. 2025. Targeting lysozyme 2 in endocardium promotes rapid recovery by modulating remote injury signals.. Cell Stem Cell 32(10):1563-1576.e11 PMID: 40967223
- 5. Zhang J et al.. 2026. Skeletal Muscle HSF1 Alleviates Age-Associated Sarcopenia and Mitochondrial Function Decline via SIRT3-PGC1α Axis.. Adv Sci (Weinh) 13(11):e10368 PMID: 41400028
- 6. van der Ven CFT et al.. 2020. Non-coding RNAs in Cardiac Regeneration.. Adv Exp Med Biol 1229:163-180 PMID: 32285411
- 7. Han Y et al.. 2024. Optogenetic Stimulation of the Cardiac Vagus Nerve to Promote Heart Regenerative Repair after Myocardial Infarction.. Int J Biol Sci 20(6):2072-2091 PMID: 38617528
- 8. Pei L et al.. 2024. Thrombospondin 1 and Reelin act through Vldlr to regulate cardiac growth and repair.. Basic Res Cardiol 119(1):169-192 PMID: 38147128
